Somewhat Positive News Coverage Somewhat Unlikely to Affect SAGE Therapeutics (SAGE) Share Price
News headlines about SAGE Therapeutics (NASDAQ:SAGE) have been trending somewhat positive recently, according to Accern Sentiment. The research group rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. SAGE Therapeutics earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 44.876465149875 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the media headlines that may have impacted Accern’s rankings:
- SAGE Therapeutics (SAGE) vs. aTyr Pharma (LIFE) Financial Survey (americanbankingnews.com)
- Stephen Kanes Sells 44,000 Shares of SAGE Therapeutics Inc (SAGE) Stock (americanbankingnews.com)
- Dorfman colm: Wall Street analysts’ favorites fizzled in 2017 (pilotonline.com)
- Bloomberg Markets: Sage Battling Depression, Powerful Culture (bloomberg.com)
- Sage Therapeutics, Inc., (NASDAQ: SAGE) – Investor’s Roundup (Volatility Analysis) – Stock Watch (stocksnewstimes.com)
Several equities analysts have weighed in on SAGE shares. Royal Bank of Canada boosted their target price on shares of SAGE Therapeutics from $117.00 to $120.00 in a report on Thursday, November 2nd. Leerink Swann boosted their target price on shares of SAGE Therapeutics from $123.00 to $246.00 in a report on Thursday, December 7th. Bank of America decreased their target price on shares of SAGE Therapeutics from $103.00 to $101.00 and set a “buy” rating on the stock in a report on Thursday, November 16th. BMO Capital Markets restated a “buy” rating and issued a $80.00 price objective on shares of SAGE Therapeutics in a report on Friday, October 27th. Finally, SunTrust Banks set a $82.00 price objective on shares of SAGE Therapeutics and gave the stock a “buy” rating in a report on Thursday, October 19th. One analyst has rated the stock with a sell rating, three have given a hold rating and twelve have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $171.21.
SAGE Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) EPS for the quarter, topping the consensus estimate of ($1.98) by $0.01. The business’s revenue was up .0% on a year-over-year basis. analysts forecast that SAGE Therapeutics will post -7.42 earnings per share for the current fiscal year.
In related news, CEO Jeffrey M. Jonas sold 210,247 shares of the company’s stock in a transaction that occurred on Thursday, December 21st. The shares were sold at an average price of $157.45, for a total transaction of $33,103,390.15. Following the sale, the chief executive officer now directly owns 211,473 shares of the company’s stock, valued at approximately $33,296,423.85. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Albert Robichaud sold 60,000 shares of the company’s stock in a transaction that occurred on Thursday, December 14th. The stock was sold at an average price of $159.43, for a total transaction of $9,565,800.00. Following the sale, the insider now directly owns 152,759 shares in the company, valued at $24,354,367.37. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 314,247 shares of company stock worth $50,465,110. Company insiders own 6.10% of the company’s stock.
TRADEMARK VIOLATION WARNING: This article was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2018/01/16/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-sage-therapeutics-sage-share-price.html.
About SAGE Therapeutics
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.